Innate Pharma S.A.
IPHA
$2.07
$0.041.97%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -7.85% | 14.72% | 3.04% | -1.91% | 0.85% |
| Total Depreciation and Amortization | 7.85% | -18.08% | -3.03% | -23.80% | -0.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.85% | 165.20% | -3.04% | 2,175.91% | -0.91% |
| Change in Net Operating Assets | -7.85% | -211.37% | -3.04% | -51.75% | -0.85% |
| Cash from Operations | -7.85% | -209.76% | 3.04% | -434.14% | -0.85% |
| Capital Expenditure | -7.87% | 47.05% | 3.03% | 61.00% | 0.85% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 7.85% | -17.12% | -3.04% | 604.11% | -0.85% |
| Cash from Investing | 7.85% | -16.73% | -3.04% | 806.06% | -0.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 1.33% | 0.00% | -2.17% | 0.00% |
| Issuance of Common Stock | 0.00% | 426.70% | 0.00% | 2,948.39% | 0.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 7.85% | 715.27% | 3.04% | 60.32% | 0.85% |
| Foreign Exchange rate Adjustments | 7.85% | 506.73% | 3.01% | 1.45% | 0.86% |
| Miscellaneous Cash Flow Adjustments | -- | -- | 16.67% | -- | -- |
| Net Change in Cash | -7.85% | -248.64% | 3.04% | -495.96% | 0.87% |